BeOne Medicines Announces Its Data From Phase 3 HERIZON-GEA-01 Study Confirms Benefits Of TEVIMBRA + ZIIHERA To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Loading news article.

BeOne Medicines Announces Its Data From Phase 3 HERIZON-GEA-01 Study Confirms Benefits Of TEVIMBRA + ZIIHERA To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma | WAPE

BeOne Medicines Announces Its Data From Phase 3 HERIZON-GEA-01 Study Confirms Benefits Of TEVIMBRA + ZIIHERA To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Article summary

Related companies

Comments —